Tech Company Financing Transactions
Alto Neuroscience Funding Round
Alto Neuroscience closed a $50 million funding round on 10/20/2025. Investors included Perceptive Advisors, Commodore Capital and private investors.
Transaction Overview
Company Name
Announced On
10/20/2025
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Alto intends to use the proceeds from the PIPE to accelerate the development of ALTO-207, a fixed-dose combination of pramipexole (a dopamine D3-preferring D3/D2 agonist) and ondansetron, following a successful FDA meeting regarding the development path of the program, as well as for working capital and general corporate purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
369 South San Antonio Rd.
Los Altos, CA 94022
USA
Los Altos, CA 94022
USA
Phone
Undisclosed
Website
Email Address
Overview
Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Amit Etkin
Chief Medical Officer
Adam Savitz
Chief Operating Officer
Daniel Segal
Co-Founder
Wei Wu
Vice President
Bruce Morimoto
VP - Bus. Development
Nick Smith
VP - Operations
Lesley Parker
Browse more venture capital transactions:
Prev: 10/20/2025: Grail venture capital transaction
Next: 10/20/2025: Safe Pro venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs